Eu Yang Sang International Ltd
BACKGROUNDThe Company was incorporated in Singapore on 10 April 1993 under the name of Videlli Pte Ltd which was subsequently changed to Eu Yan Sang International Holdings Pte Ltd on 1 September 1993. On 6 July 2000, it was converted into a public company and adopted its present name.
The principal activities of the Company are investment holding and the provision of management services to the Group. Today, EYS manufactures and markets fine quality, Chinese herbs, Chinese Proprietary Medicines as well as health foods. EYS currently offers more than 250 products under its “Eu Yan Sang” brand name and over 1,000 different types of
Chinese herbs and other medicinal products. Manufacturing facilities are carried out in its three GMP-certified (Good Manufacturing Practice) factories in Hong Kong and Malaysia.
EYS's distribution network comprising of over 90 retail outlets in Hong Kong, Malaysia, Singapore and USA. “Eu Yan Sang” products are available in over 6,000 drugstores, pharmacies, medical halls, hospitals, supermarkets, chain stores, health clubs, spas and convenience stores worldwide. Its cybershop at www.euyansang.com.sg offers its global customers the ease and convenience of purchasing online.
In addition, EYS operates a chain of 13 TCM clinics in Singapore and Malaysia; 3 Specialist TCM clinics in Singapore; 4 “YourHealth” Integrative Medicine Centres (IMC) in Australia. The Specialist TCM clinics and IMCs combine the best practices of conventional medicine, TCM and other natural therapies, providing modern consumers with a holistic approach to healthcare.
COPORATE WEBSITE: http://www.euyansang.com
The principal activities of the Company are investment holding and the provision of management services to the Group. Today, EYS manufactures and markets fine quality, Chinese herbs, Chinese Proprietary Medicines as well as health foods. EYS currently offers more than 250 products under its “Eu Yan Sang” brand name and over 1,000 different types of
Chinese herbs and other medicinal products. Manufacturing facilities are carried out in its three GMP-certified (Good Manufacturing Practice) factories in Hong Kong and Malaysia.
EYS's distribution network comprising of over 90 retail outlets in Hong Kong, Malaysia, Singapore and USA. “Eu Yan Sang” products are available in over 6,000 drugstores, pharmacies, medical halls, hospitals, supermarkets, chain stores, health clubs, spas and convenience stores worldwide. Its cybershop at www.euyansang.com.sg offers its global customers the ease and convenience of purchasing online.
In addition, EYS operates a chain of 13 TCM clinics in Singapore and Malaysia; 3 Specialist TCM clinics in Singapore; 4 “YourHealth” Integrative Medicine Centres (IMC) in Australia. The Specialist TCM clinics and IMCs combine the best practices of conventional medicine, TCM and other natural therapies, providing modern consumers with a holistic approach to healthcare.
COPORATE WEBSITE: http://www.euyansang.com
Pharmesis International Ltd
BACKGROUNDThe Company was incorporated in Singapore on 29 September 2003 under the name of Sinopharm Pte Ltd and it changed its name to Pharmesis International Pte Ltd on 16 April 2004. It adopted its current name on 30 August 2004.
Pharmesis specializes in the manufacture of pharmaceutical products, including western medicine and Traditional Chinese Medicine (“TCM’’).
Under its two subsidiaries, Kinna Pharm and Longlife, it specializes in the manufacturing of pharmaceutical products in the form of tablets, granules, pills, etc, including TCM formulated products for the treatment of illnesses relating to the liver and gall bladder. Its two main products are ATT tablets and Gansu granules. Additionally, its business also includes the research and development, production, sale and marketing of pharmaceutical products. These pharmaceutical products are sold in China and they include western medicine products under the “国嘉 ” brand, while its TCM formulated products are sold under the “古蔺肝苏 ” brand.
Leveraging its research and development capabilities and in-house expertise in pharmaceutical products for the treatment of illnesses relating to the liver and gall bladder, Pharmesis has successfully obtained the license to produce ATT tablets in China. Similarly, it is the only Group with the right to produce Gansu granules from Ganhuangcao in China.
With sales and marketing network of approximately 900 sales personnel across China, its products can be found in 2,000 hospitals in many cities within China.
The Group's two production facilities are located in Chengdu and Gulin, China.
COPORATE WEBSITE: http://www.pharmesis.com
Pharmesis specializes in the manufacture of pharmaceutical products, including western medicine and Traditional Chinese Medicine (“TCM’’).
Under its two subsidiaries, Kinna Pharm and Longlife, it specializes in the manufacturing of pharmaceutical products in the form of tablets, granules, pills, etc, including TCM formulated products for the treatment of illnesses relating to the liver and gall bladder. Its two main products are ATT tablets and Gansu granules. Additionally, its business also includes the research and development, production, sale and marketing of pharmaceutical products. These pharmaceutical products are sold in China and they include western medicine products under the “国嘉 ” brand, while its TCM formulated products are sold under the “古蔺肝苏 ” brand.
Leveraging its research and development capabilities and in-house expertise in pharmaceutical products for the treatment of illnesses relating to the liver and gall bladder, Pharmesis has successfully obtained the license to produce ATT tablets in China. Similarly, it is the only Group with the right to produce Gansu granules from Ganhuangcao in China.
With sales and marketing network of approximately 900 sales personnel across China, its products can be found in 2,000 hospitals in many cities within China.
The Group's two production facilities are located in Chengdu and Gulin, China.
COPORATE WEBSITE: http://www.pharmesis.com
STAR PHARMACEUTICAL LTD
BACKGROUNDThe Company was incorporated in Singapore on 10 January 2005 under the name of STAR Pharmaceutical Pte Ltd. It assumed the present name on 23 September 2005.
The Group is engaged in the manufacture and sale of both western and TCM-formulated prescription drugs. Its products include antibiotics, cerebrovascular drugs and cardiovascular drugs. Its market is primarily in China and sales are made through its distribution network of approximately 240 distributors to hospital, clinics and pharmaceutical. It also operates 20 liaison offices established in major cities and provinces in China.
Its manufacturing facility is based in Qionghai City. Its pharmaceutical products are available in the following administration forms:-
(a) granules, capsules, tablets;
(b) liquid for injection;
(c) lyophilised powder for injection; and
(d) powder injection.
COPORATE WEBSITE: http://www.hnstar.com.cn
The Group is engaged in the manufacture and sale of both western and TCM-formulated prescription drugs. Its products include antibiotics, cerebrovascular drugs and cardiovascular drugs. Its market is primarily in China and sales are made through its distribution network of approximately 240 distributors to hospital, clinics and pharmaceutical. It also operates 20 liaison offices established in major cities and provinces in China.
Its manufacturing facility is based in Qionghai City. Its pharmaceutical products are available in the following administration forms:-
(a) granules, capsules, tablets;
(b) liquid for injection;
(c) lyophilised powder for injection; and
(d) powder injection.
COPORATE WEBSITE: http://www.hnstar.com.cn
TRANSCU GROUP LIMITED
Transcu Group Limited is a Life Sciences company, engaged in the research, development and commercialisation of cutting-edge technologies to improve and enhance the Quality of Life. Established in 1988 in Japan and headquartered in Singapore, the Group has offices in Singapore, Japan and the United States.
Its current focus includes transdermal drug delivery systems and specialised cosmetic products for the pharmaceutical and cosmeceutical industries. Transcu’s transdermal drug delivery technologies allow the local and systemic delivery of drugs through the skin into the body. This innovative, pain-free, non-invasive method can be customised for a wide variety of medical, pharmaceutical and cosmeceutical applications, as an alternative to injections, oral pills and other drug delivery methods such as transmucosal and inhalation.
As a knowledge-based company, Transcu holds patents for three device inventions and has over 500 live filings for patents applications and formulations worldwide.
Transcu has already succeeded in generating revenues from licensing its proprietary technologies to strategic business partners and anticipates sustainable revenues from manufacturing, distribution and sale of end-products using its proprietary technologies.
COPORATE WEBSITE:
Its current focus includes transdermal drug delivery systems and specialised cosmetic products for the pharmaceutical and cosmeceutical industries. Transcu’s transdermal drug delivery technologies allow the local and systemic delivery of drugs through the skin into the body. This innovative, pain-free, non-invasive method can be customised for a wide variety of medical, pharmaceutical and cosmeceutical applications, as an alternative to injections, oral pills and other drug delivery methods such as transmucosal and inhalation.
As a knowledge-based company, Transcu holds patents for three device inventions and has over 500 live filings for patents applications and formulations worldwide.
Transcu has already succeeded in generating revenues from licensing its proprietary technologies to strategic business partners and anticipates sustainable revenues from manufacturing, distribution and sale of end-products using its proprietary technologies.
COPORATE WEBSITE:
Tianjin Zhong Xin Pharmaceutical Group Corporation
BACKGROUNDIn the 1950s, with the China government's policy of merging state-owned pharmaceutical enterprises with the private sector, Tianjin Municipal Chinese Medicinal Materials Corpn (TMCM) merged and reorganised the various factories and stores in Tianjin. In December 1992, TMCM was converted from a state-owned enterprise to a company limited by shares whereby shares were issued to legal persons and its employees. In connection therewith, it was renamed Tianjin Traditional Chinese Medicine Group Co Ltd (TTCM). Following the corporatisation of the Company, the shares issued to the employees were traded at the Tianjin Securities Trading Centre.
In conjunction with the proposed public offering, TTCM adopted its present name. Pursuant to the restructuring, it became the holding company for the Group.
The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese medicinal drinks, Chinese medicinal raw materials, biotechnology medicine, chemical raw material medicine and preparations, and nutritional and health products. It has over 800 medicinal products in over 20 types of formulations. The main products are Suxiao Jiuxin pill (used for treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment of intestines and stomach disease), Gengnian An (used for treatment of menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu Zhuyu capsule (used for treatment of diseases relating to heart and head blood vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of diabetes), and Te Zi She Fu (used for diminishing inflammation).
The holding company and ultimate holding company is Tianjin Pharmaceutical Hldgs, a company incorporated in Tianjin, China.
COPORATE WEBSITE:
In conjunction with the proposed public offering, TTCM adopted its present name. Pursuant to the restructuring, it became the holding company for the Group.
The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese medicinal drinks, Chinese medicinal raw materials, biotechnology medicine, chemical raw material medicine and preparations, and nutritional and health products. It has over 800 medicinal products in over 20 types of formulations. The main products are Suxiao Jiuxin pill (used for treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment of intestines and stomach disease), Gengnian An (used for treatment of menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu Zhuyu capsule (used for treatment of diseases relating to heart and head blood vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of diabetes), and Te Zi She Fu (used for diminishing inflammation).
The holding company and ultimate holding company is Tianjin Pharmaceutical Hldgs, a company incorporated in Tianjin, China.
COPORATE WEBSITE:
C & O Pharmaceutical technology (Holdings) Limited
BACKGROUNDC & O Pharmaceutical Technology (Holdings) Limited was incorporated in Bermuda on 28 July 2003.
The Group's principal business activities are carried out in China and include research, manufacturing, marketing and distribution of C&O branded pharmaceutical products as well as distribution of third party pharmaceutical products in all the provinces of China. The Group's manufacturing facilities are located in Nanjing City, China.
The Group's current portfolio of products includes four imported pharmaceutical products and 24 C&O branded pharmaceutical products, most of which are included in the National Health Insurance Scheme. To sustain a continuous stream of new products launch, the Group maintains a development pipeline of over 50 new products. The Group is also working on 10 new compounds with the potential for international patent applications.
Currently, the Group's distribution network covers more than 3,000 distributors and over 300,000 clinics, pharmacies and hospitals across the whole of China.
COPORATE WEBSITE: http://www.changao.com
The Group's principal business activities are carried out in China and include research, manufacturing, marketing and distribution of C&O branded pharmaceutical products as well as distribution of third party pharmaceutical products in all the provinces of China. The Group's manufacturing facilities are located in Nanjing City, China.
The Group's current portfolio of products includes four imported pharmaceutical products and 24 C&O branded pharmaceutical products, most of which are included in the National Health Insurance Scheme. To sustain a continuous stream of new products launch, the Group maintains a development pipeline of over 50 new products. The Group is also working on 10 new compounds with the potential for international patent applications.
Currently, the Group's distribution network covers more than 3,000 distributors and over 300,000 clinics, pharmacies and hospitals across the whole of China.
COPORATE WEBSITE: http://www.changao.com
CHINA ANIMAL HEALTHCARE LIMITED
BACKGROUNDThe Company was incorporated in Bermuda on 10 August 2000 under the name Colorland Animation Ltd and changed its name to China Animal Healthcare Ltd on 31 December 2007 following the completion of the acquisition of Evanton Pte Ltd.
The Group is principally engaged in the manufacture, sale and distribution of animal drugs for poultry and livestock in China. The Group’s products are sold directly to animal drug retailers and large-scale poultry enterprises throughout China. As a value-added service to selected customers who meet their sales target or whom the Group is of the view has sales potential, the Group also provides technical and support services such as farming techniques and methodologies and to impart knowledge relating to animal health and treatment of animal diseases.
COPORATE WEBSITE : http://www.chinanimalhealthcare.com
The Group is principally engaged in the manufacture, sale and distribution of animal drugs for poultry and livestock in China. The Group’s products are sold directly to animal drug retailers and large-scale poultry enterprises throughout China. As a value-added service to selected customers who meet their sales target or whom the Group is of the view has sales potential, the Group also provides technical and support services such as farming techniques and methodologies and to impart knowledge relating to animal health and treatment of animal diseases.
COPORATE WEBSITE : http://www.chinanimalhealthcare.com
